Opticology Inc. will exhibit at SPIE BiOS 2018, a biomedical optics conference preceding SPIE Photonics West. January 19, 2018
Opticology Inc. will exhibit at SPIE BiOS 2018, a biomedical optics conference preceding SPIE Photonics West. The company intends to showcase its abilities as a contract developer of medical and scientific instruments.
Work samples of prototype devices will be on hand as will some of the OEM components it builds for its design clients.
Opticology to Exhibit at SPIE BiOS 2017, the largest biophotonics, biomedical optics, and imaging conference. January 7, 2017
Opticology Inc. will exhibit at SPIE BiOS 2017, a biomedical optics conference preceding SPIE Photonics West. The company intends to showcase its abilities as a contract developer of medical and scientific instruments. Work samples of prototype devices will be on hand as will some of the OEM components it builds for its design clients.
In addition to Opticology's core contract business, the company will also have on display work from its internal development business Opticology Research which is the development arm of the company which has spun off four companies in the medical device and environmental testing fields.
Opticology's Affiliate Tear Glucose Research Featured in National Institute for Health Research (UK) Horizon Scanning Review "New and Emerging Non-Invasive Glucose Monitoring Technologies" May 16, 2016
Tear Glucose Research (TGR), a spin off company of Opticology, Inc. is named as one of 40 companies identified developing non-invasive glucose monitoring technology to replace finger-stick blood glucose meter currently used by millions who suffer from diabetes. Other companies named in the report include big players Abbott Diabetes Care, Novartis Alcon (Google), and Freedom Meditech.
TGR uses an optical technique, surface plasmon resonance, to measure glucose concentrations in the ocular tears which are known to track blood glucose levels in the body. The device is in the form of a small pen-shaped probe with a small tip sensitized with proprietary glucose sensing chemistry.
Opticology Registers for International Traffic in Arms Regulations (ITAR) October 7, 2015
In an effort to continue its broad appeal to clients in various industries, Opticology, Inc. has completed registration for ITAR through the US Department of State Office of Defense Trade Controls Compliance. ITAR registration is required for companies engaged in manufacturing or exporting defense articles or services pursuant to the Arms Export Control Act. The International Traffic in Arms Regulations (ITAR) website
Opticology Research files patent for field portable detection device June 12, 2015
The company announced today the filing of an important patent as a result of the work of its research business unit of a field portable system for the detection of chemical and biological agents. Principal Engineer Anthony Cappo comments "We are considered experts in the field of custom surface plasmon resonance (SPR) instruments and in particular miniaturized units. Our clients have expressed a need for a field portable version of the technology that can be used in hostile environments and our latest technology developments fits that bill."
The company intends to commercialize the field-portable sensor platform for a host of detection modalities including heavy metals, residual explosives, or infectious disease that can be measured with precision without the need for laboratory analysis.
Opticology Founder Featured in Crain's New York Business for Work on Tear Glucose August 5, 2014
Tear Glucose Research, LLC, a biotechnology company spun out of Opticology, Inc. is featured in Crain's New York Business. In the article "Six biotech startups to watch", the company and its founder are featured for the development of a hand held sensing probe to measure the amount of glucose in human tears, a direct correlation to blood glucose.
Team Wins Funding from New York City Economic Development Corporation for Tear Glucose Studies June 27, 2013
Opticology, Inc. and the New York Eye & Ear Infirmary have been awarded funding for continued development of a diagnostic device for measuring glucose levels in the human tear film. The device has the potential to replace or supplement current finger-prick blood glucose meter used by diabetics, without the pain and inconvenience of drawing blood. Tear glucose can be measured with a gentle touch just above the lower eyelid with a small, portable, pen shaped device.
With the funding, the team will have the opportunity to conduct a clinical study of their handheld device and glucose sensitive chemistry which is attached to the device tip. The award was granted under a New York City Economic Development Corporation initiative PILOT Health Tech NYC.
In partnership with New York Eye & Ear Infirmary and the Lighthouse International, both of New York, Opticology principals Anthony Cappo and Matthew Orr will present their findings from a clinical study entitled A New Method to Depict Central Scotomas: Automated Stereocampimetry at the 2013 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle this coming May.
Opticology has worked closely with medical researchers in the development of this new device which can measure with precision pathological areas of non-vision on the retina, or scotomas, typically found in patients with age-related macular degeneration or diabetic retinopathy. The device consists of minimal hardware, controlled by software and is installed compactly on modern ophthalmic examination chair swing arm. It is meant to be a low cost alternative yet provide valuable information to the clinician regarding diagnosis and following disease after treatment.
Additional Tear Diagnostic Patent Issues August 21, 2012
Opticology announced today the issuance of US Patent # 8,249,682 describing a device for measuring concentrations of constituents in tear samples. Long time colleagues Anthony Cappo and Diptabhas Sarkar have spun out a company to commercialize the device for measuring glucose in human tears as an alternative to monitoring blood glucose through finger pricks.
The patent is also being applied toward detection of dye eye syndrome, proteins, viruses, bacteria and other constituents that manifest in the ocular tear film.
Opticology Offshoot Receives Notice of Allowance of Important Patent May 12, 2012
Opticology announced today that a key US patent for one of its spin-off companies has received a Notice of Allowance from the US patent office. Opticology principal Anthony P. Cappo is primary inventor on the patent which focusses on non-invasive diagnostics via the ocular tear film. Opticology is involved in the development of a new device to measure glucose concentrations in ocular tears as a non-invasive means of determining blood glucose without drawing blood.
The spin-off company, Tear Glucose Research, LLC, has an exclusive license to the patent for glucose determination in tears. The company is developing a novel biosensor and the accompanying handheld device which promises to be a convenient and painless means to measure blood glucose in diabetics.
Opticology Founder Anthony Cappo Featured on Fox Business News August 2, 2011
In-stock Absorptive Density Filters – UV,
VIS, NIR – available for online purchase March 10, 2011
A long time supplier of custom optical filters, Opticology
announced that effective April 1st 2011, it will offer a stock line of
filters in incremental optical densities designed for the ultraviolet,
visible, and near infrared wavelengths. Stock sizes, and density values,
and neutral density filter sets, will be offered for purchase via the company
website at the Opticology.com
- Online Catalog.
The company plans to introduce stock shortpass, bandpass, and longpass
absorptive type filters also available for purchase online in the 4th quarter
Opticology Spins off Non-Invasive Glucose Co. April 17, 2010
Principals at Opticology have formed a company to commercialize a new
device for measuring glucose concentrations in human tears. The patented
technology developed internally at Opticology, is intended as a means to
non-invasively measure blood sugar in diabetics. The new company, Tear
Glucose Research, LLC, is in cooperation with a university chemistry laboratory
and a research hospital. The company is developing a highly sensitive glucose-specific
ligand for direct detection of glucose levels in the body via ocular tears.
Principal Engineer Awarded Broad Patent for Human Tear Diagnostics August 1, 2008
Anthony P. Cappo, Principal Optical Engineer at Opticology, Inc., is the
primary inventor on US Patent #7,395,103 which issued July 2008. The patent
provides broad protection for a handheld portable probe employing Surface
Plasmon Resonance Spectroscopy to directly probe the human tear film. Worldwide
patents are pending.
Opticology Principals Ophthalmic Device Patent Issues December 21, 2007
A key patent in ophthalmic diagnostics issued December 18th. Opticology
principals Anthony Cappo and Matthew Orr are key inventors to technology
used to measure areas of non-vision in cases of diabetic retinopathy and
age-related macular degeneration.
The patent has been assigned to Centrofuse Technologies, LLC.
Tear Diagnostics Moves Towards Commercial Development April 3, 2007
Opticology announced today that it has assigned its rights and interest
to a patent application related to dry eye diagnostics to a new company
aptly named LacriSciences, LLC. The new company will focus on commercial
development of a direct probing osmometer for detection of dry eye. The
company plans to explore using the device for other means of disease detection
that manifest in the tear film including bacterial and viral infections.
The company was formed in partnership with world renowned expert on dry
eye and the ocular tear film Jeffrey P. Gilbard, MD. Dr. Gilbard was the
first to develop tear osmolarity as a diagnostic test in 1976, and is the
Founder, CEO and Chief Scientific Officer of Advanced Vision Research,
makers of TheraTears. Opticology will continue to participate in the early
stage design and development of the device.
NIH Funds Dry Eye Diagnostic
Inc. (New York,
NY) has been granted a Phase I STTR award
for the continued development of a Nanoliter Tear
Osmometer in cooperation with the Aborn Eye Research Center (New York, NY).
The award was made by the
National Institutes of Health’s
National Eye Institute.
Tear osmolarity, well accepted as the objective measure for
presence and degree of Dry Eye Syndrome, is not widely used in clinical
practice due to the lack of a commercially available osmometer
that can measure nanoliter sample volumes.
is believed to be a disruption in the stability of the tear
Eye Syndrome caused by a deficiency of one of the three components that make up a
tear. Dry Eye affects a large percentage of the population with symptoms
predominately of discomfort, yet can cause progressive pathological changes
in the conjunctiva and corneal epithelium.
it prevalence, Dry Eye has been difficult to accurately diagnose, as the
Dry Eye symptoms can be misinterpreted as evidence of other
conditions. The recent introduction
of prescription pharmaceuticals for Dry Eye treatment has accentuated the
lack of instrumentation engineered specifically for Dry Eye detection, and
thereby heightened the timeliness of Opticology’s research.
Opticology, Inc. Expands Product Development Group
August 10, 2004
Opticology announced today the expansion of its Product
Development Group to further broaden and solidify the company’s role in
prototype development and innovative optical engineering solutions. The
enhancements will streamline prototyping services for the medical device
industry, corporate and academic level R&D, and core business customers.
Improvements include a 4-axis computer controlled
machining center, the addition of state-of-the-art CAD and CAM software, and
several improvements to the physical workspace. Furthermore, the onsite
staff has been expanded to include an Industrial Designer.
“Our customers expect their jobs to be done quickly, and
done right” explains Tony Cappo, Principal Engineer at Opticology. “The
expanded capability allows us to get more of the job done in-house, avoiding
the pitfalls with outside labor. Both our clients and our internal projects
will experience more innovative designs, even more attention to detail, and
a faster development cycle.”
The growth continues Opticology’s history of designing
and building custom optical and opto-mechanical systems. In response to the
increased use of optics in medical devices and the like, full services are
offered in proof-of-concept, prototype, and production-ready systems.
NIH Awards Phase II STTR Grant to Opticology, Inc. and Aborn Eye Research Laboratory
Opticology, Inc. (New York,
NY) has been awarded a Phase II Small
Business Technology Transfer grant in collaboration with the Aborn Eye Research Laboratory (New York, NY)
from the National Institutes of Health’s National Eye Institute.
The two will continue research funded in Phase I, toward the development of
a visual field device specifically designed to accurately depict centrally
located pathological areas of non-vision on the retina.
The alliance has developed a prototype ophthalmic
instrument which addresses the shortcomings of commercially available
perimeters, which fail to produce accurate results in patients with
centrally located retinal defects such as age-related macular degeneration
and diabetic retinopathy due to their inability to fixate. The instrument
uses a combination of sophisticated software and optical hardware and has
been clinically shown to enable patients to maintain fixation during an
exam, allowing measurements of the central and paracentral
visual field with unprecedented accuracy.
The intention of the Phase II research is to design the
instrument for commercialization and incorporate all the features of a
modern perimeter, with the ability to render an accurate depiction of
central retinal defects previously unattainable in an office setting.
Clinical trials will continue at the New York Eye & Ear Infirmary
(New York, NY).
Opticology Introduces Beta Version of Full-Color LED
Based Fiber Optic Illuminator January 31, 2003
Opticology, Inc. has released preliminary product that
has applications in machine vision and general color-sensitive systems
requiring optical illumination. The unit launches light from multiple
ultra-bright LED’s into a ½ diameter fiber bundle. Light output is
adjustable in intensity, but also color – either
pure red, green, or blue OR any mix of the three allowing the user
to obtain virtually any color output. Even varying shades of white can be
produced yellow-white, blue-white, etc. mimicking varying color
Ideal for machine vision applications where illumination
of objects in a particular color band can boost signals. Also beneficial
for transilluminated and reflected microscopy
where colored illumination is beneficial and heat can cause problems.
The device benefits from advantages of LED’s
– low power consumption, long lifetimes, and minimal heat generation.
There are no bulbs to replace, no bulk transformers, no fans, and the
output light does not vary with time. No color filters, no heat filters,
on-the-fly color adjustment, and high output. Opticology is offering custom
versions of the device at this time, competitively priced with conventional
NIH Awards Grant to Ophthalmic Research Laboratory and Optical
Engineering Firm October 24, 2001 A Phase I Small Business Technology Transfer grant has been awarded to Opticology, Inc. (New York, NY) in
conjunction with the Aborn Eye Research Center (New York, NY), for the
continued development of an ophthalmic device to accurately measure
centrally located pathological areas of non-vision on the retina. The award
has been made by the National Institutes of Health’s National Eye
The alliance has demonstrated new technology that
enables a patient that suffers from diseases such as macular degeneration
and other centrally located retinal defects to maintain fixation, enabling
measurements of their central and paracentral
visual field with unprecedented accuracy. It is intended to make the device
available clinically, and uses a combination of sophisticated software and
optical hardware to perform the measurements. Clinical trials of the
prototype device will be performed at the New York Eye and Ear Infirmary (New York, NY).
Opticology, Inc., Old Chelsea Station, P.O. Box 1080, New York, NY10113. Tel: 212-243-4328; Fax: